Molecular Targeting of Triple Negative Breast Cancer, a promising therapeutics alternative or a necessity

دوازدهمين كنگره بين المللي سرطان پستان

4 الي 6 اسفند 1395، تهران - ايران

Presentation Type: Poster
Abstract: Introduction: Triple-negative breast cancers (TNBC) is a worse prognosis with high mortality rate and tending to early relapsing compared with other subtypes of breast cancer. TNBCs are defined as tumors that lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 and have overlapping with Basal like subgroup of breast cancer. Although chemotherapy is widely administered in triple-negative cancer, outcome remains relatively poor. It is not surprising though the molecular target specific therapeutics becomes attractive as an alternative. However, choosing a specific target and strategy to encounter heterogeneous complexity nature of TNBCs will no mean feat. On the other hand, Immunotherapy especially in combination to other treatments is the novel approach combating TNBCs which has led to improve clinical outcomes.
Aims and scopes: Receptor tyrosine kinase including EGFR, FGFR and TGF-b receptor target involved in many cell procedures such as cell growth, proliferation, differentiation as well as cell survival and apoptosis thus considered as common targets in Breast cancers . Some strategies such as using Poly-ADP Ribose Polymerase Inhibitors (PARPi) as a part of DNA-damage response (DDR) pathway which is related to base-excision repair after DNA damage, have gained a frequent attention. Targeting DNA damage-induced cell cycle arrest such as DNA damage checkpoint kinases including ATM , ATR and check point kinase ½ is one of the main missions as the necessity of filling the gap of the lack of a reliable target for treatment.